We would love to hear your thoughts about our site and services, please take our survey here.
very strange this morning ADVFN news for OPTI was on first thing even before https://www.investegate.co.uk/ and could not see any sign of it on this site
01 June 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Appointment of Cambridge Commodities as UK distributor
Non-exclusive distribution agreement with ProBiotix Health Ltd
OptiB i ot i x H ealth p l c (A I M :O P TI), a li f e sc i ences bu s i n ess d e ve l o p i n g c o m p o u n d s to tack l e o b esi t y, h i g h cholesterol, diabetes and skin care, a nnounces that its wholly-owned subsidiary, ProBiotix Health Ltd. ("ProBiotix"), has entered into a non-exclusive distribution agreement with Cambridge Commodities Ltd ("CCL") for the distribution of LP(LDL) (R) and CholBiome(R) (x3) in the UK .
The agreement grants CCL a non-exclusive licence to distribute ProBiotix's specialty ingredient LP(LDL) (R)as well as the finished dietary supplement CholBiome(R) (x3) for cholesterol and blood pressure reduction.
CCL is one of the UK's leading specialty ingredients suppliers. The agreement extends the commercial reach of LP(LDL) (R) into new application areas where CCL has specific sector expertise, such as food and beverage, sports nutrition, health & wellbeing and beauty. The agreement builds on OptiBiotix's existing relationship with CCL (RNS: 28 January 2020) which led to the successful launch of SlimBiome(R) in Holland and Barrett.
CCL is a supplier of nutritional ingredients to major UK retailers, and supplement companies. CCL has 10 sales offices which cover the UK, Europe, USA and South Africa with a multi-million pound annual turnover ( https://www.cambridgecommodities.com/home.htm ). LP(LDL) (R) and CholBiome(R) (x3) , are fully patented products and of natural origin developed by experts to provide documented significant reductions of LDL-cholesterol, as well as blood pressure levels which combined reduce the risk of Cardiovascular Disease multiplicatively. The products will be purchased from ProBiotix and distributed by CCL in UK. The agreement is based on minimum order quantities.
ProBiotix was created to develop science based healthy lactic acid bacteria called probiotics to reduce cardiovascular risk. Independent clinical studies have shown LP(LDL) (R) probiotic can reduce key cardiovascular bio-markers such as total cholesterol, LDL (bad) cholesterol, and blood pressure by up to 36.7%, 13.9% and 5.1% respectively. Since launching its CholBiome(R) products containing LP(LDL) (R) in May 2017, ProBiotix has signed over 30 agreements and its products are now commercialised in approximately 43 countries. LP(LDL) (R) was designated Generally Recognized As Safe ("GRAS") by an independent Expert GRAS Panel in the United States in February 2019, which extends its applications from use as a supplement to use as a functional ingredient in a wide range of food, dairy, and beverage products in the USA.
Mikkel Hvid-Hansen, Commercial Director of ProBiotix Health Ltd., commented: "We are pleased to announce the signing of the distribution agreement with CCL. We chose them due to their leading mark
SHEEPHATCH this link for company news 7 00 am onwards
https://www.investegate.co.uk/
NEX is now called AQUIS ECHANGE, jb beat me to it
22/05/2020 08:16 1,010,101 0.099
GodWilling £5 per deal with IWEB
the MM,s churning the shares to make dosh
16 April 2020
TP Group plc
("TP Group", the "Company" or the "Group")
Development of flexible on-site medical gas production
Initiative seeks to increase sustainability and responsiveness to peak loading
TP Group (AIM: TPG), the providers of mission-critical solutions for a more secure world, announces that it has commissioned a development programme ('the Programme') to build modular gas production equipment in response to emerging requirements.
Recent events, particularly the COVID-19 outbreak, have drawn attention to the availability of oxygen for critical care, particularly under peak load, which has highlighted challenges in logistics, contingency planning and flexibility in the supply of medical gases.
The Programme is intended to produce modular systems that can be deployed on demand at hospitals and other facilities suitable for on-site gas production. TP Group has significant experience in the field having worked for more than forty years on innovative approaches to gas production using electrolysis.
The Programme was initiated in late 2019 and has been accelerated to meet emerging needs. It is currently funded from TP Group's existing resources and will last a further three months. In that time, proven technologies developed under a range of submarine life support programmes will be combined to generate low-carbon supplies of hydrogen or oxygen according to end-user requirements. The first phase of the project aims to produce a demonstration system at the Group's Portsmouth facility that can be tested for suitability and performance. From there, it is anticipated that future modular units to suit a range of needs can be specified in consultation with customers and partners for development activities to commence in the second half of 2020.
As well as the near-term benefits in flexible gas production, this Programme will also contribute to longer-term sustainability goals, through a reduction in carbon dioxide and nitrous oxide emissions in the existing supply chain, as well as decreased transportation costs. This is particularly key in the UK healthcare sector, where the National Health Service produces roughly five per cent of the UK's greenhouse gasses, and the NHS Sustainable Development Plan aims to eliminate 80 per cent of the 1990 baseline carbon emissions by 2050.
Phil Cartmell, Chief Executive Officer of TP Group, commented:
"I am very pleased that in these challenging times, the TP Group team has been able to look creatively at both our technologies and capabilities and sought to apply them in new ways that are relevant to the current challenges we face."
"When proven, we anticipate these systems will be able to produce medical and other gases locally at the point of consumption, potentially reducing carbon usage in both production and transportation."
02 April 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
SlimBiome(R) contract manufacturing agreement with Fipros A/S
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.
Fipros ( www.fipros.dk ) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome(R) under licence.
This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome(R) in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division , c o mmented: "We are very pleased to work with Fipros to manufacture SlimBiome (R) within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."
31 March 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Exclusive licence agreement for OptiBiome(R) with OptiPharm Pty Ltd.
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high
choleste r ol, diabetes and skincare, a nn o unces it has entered into an exclusive licence agreement for the use of its OptiBiome(R) weight management ingredient with OptiPharm Pty Ltd. ("OptiPharm").
OptiBiotix registered OptiBiome(R) as an alternative trademark to SlimBiome(R) to support the sale of its SlimBiome(R) ingredient in countries in which an implied health claim cannot be made (e.g. Thailand). The terms of this exclusive licence agreement grant OptiPharm exclusive use of the OptiBiome(R) trademark in over 20 markets including Australia, parts of Asia, New Zealand, Middle East, Gulf States and North America. Market exclusivity is linked to minimum order quantities.
OptiPharm ( https://www.optipharm.com ) is a privately owned Australian company currently in its 24 (th) year of operation. OptiPharm specialises in weight management, nutrition and infant formul a and their products are produced in state of the art Australian manufacturing facilities that are GMP qualified and HACCP certified (a risk based system which introduces controls at critical points of the manufacturing process).
OptiPharm's flagship brand , Optislim , is the No. 1 Australian weight management brand incorporating shakes, soups and bars available as Total (Very Low Calorie Diet) or Partial (Low Calorie Diet) Meal Replacements. Optislim is enjoyed by consumers throughout Australia, New Zealand, China, shortly the Middle East and the UAE, and is poised for release throughout South East Asia and North America. Company-owned trademarked brands include:
-- Optislim(TM) - (weight management meal replacements, including shakes, chocolate bars & soups) www.optislim.com.au
-- isustain(TM) - (nutritional meal replacements for Adults, Children & Diabetics) www.isustain.net.au
-- OPTI GOLD(TM) - (infant formula) www.optigold.com.au
Garry McDonald, Managing Director of OptiPharm, commented: "We are delighted to have completed negotiations with OptiBiotix for access to their patented ingredient OptiBiome (R) for exclusive use in over 20 markets globally. In these troubling times & with clinical research identifying a link between excess weight and one's immune system, OptiPharm are continually searching for innovative ingredients such as OptiBiome (R) , to enhance our Optislim product formulations. We look forward to working with OptiBiotix to deliver to our customers the latest in innovation, value and quality."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division , c o mmented: "We are very pleased to enter into a commercial agreement with OptiPharm to make OptiBiotix's award-winning weight management solution available to a wide range of customers th
check the NEX exchange
tell the MM,s that
just had email about new products online
25 February 2020
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
Marketing update
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high choleste r ol, diabetes and skincare, provides the following marketing update.
SlimBiome(R) is Generally Recognized as Safe ("GRAS")
OptiBiotix has self-affirmed its patented SlimBiome(R) ingredient is GRAS per US Code 21 CFR 170.30. This affirmation is based on a complete evaluation of all ingredients and processes used to manufacture SlimBiome(R) and confirmation of GRAS status for all materials used in the SlimBiome(R) formulation. GRAS status is a United States Food and Drug Administration (FDA) requirement for any ingredient or additive used in food products sold in the United States.
Online Subscription Service
OptiBiotix has introduced a subscription service for its on line store www.optibiotix.online. The service allows customers to subscribe to repeat orders and benefit from a discount on product and delivery costs. Currently the first order is 10% off, with subsequent orders thereafter at a 15% discount to help encourage continual subscription. The subscription service has been introduced to improve customer convenience and help OptiBiotix determine future demand allowing better inventory management, and support ongoing supplier discussions to reduce the cost of goods and improve margins.
Investor discount code INVESTOR20
OptiBiotix appreciates the ongoing support and feedback from its investors on existing and new products. This helps the Company improve existing products (e.g. a new smaller CholBiomeX3 tablet), and feeds directly into its new product development pipeline. It plans to launch a range of new products with retail partners, and on its online store in the coming months. These include a range of healthy snacks (e.g fruit and fibre gummies) under the SnackSmart(TM) brand, pancake mixes, a new blueberry and raspberry snack bar, and an extension of its breakfast range to include porridge containing SlimBiome(R).
In recognition of the valuable feedback OptiBiotix receives from its investors, and to broaden investor engagement in the development of new products and the success of OptiBiotix, the Company has created a new discount code, INVESTOR20. This gives investors 20% off the list price of the online product when spending over GBP45. The code cannot be used with other discount codes but can be used with the subscription service. This means that investors who subscribe and use the INVESTOR20 code can get 30% off all products (10% for subscribing and 20% off with the investor code). The code is valid for one month which may be extended or new codes offered to support product launches.
Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix is pleased to update investors on a number of developments which support the commercialisation of its ingredients and products. Self a
Science-backed products that make a difference
We've made re-ordering our products super easy with our new subscription service. Don't miss out on your science-backed product requirements by having orders automatically renew and delivered to your door as and when you want them.
Save 10% on your first delivery
Save 15% off on subsequent orders after that
Using the subscription management dashboard you can add new products, change the quantity/ frequency/ delivery date of your orders or cancel at any time should you wish.
OptiBiotix Online Subscription Guide
For 1 week only, new customers save an additional 10% on their first subscription order when adding the below code at checkout
SUBINTRO10
Shop Now
Feel fuller for longer with the GoFigure® range. Whether meal replacement shakes ideal for providing a nutritionally complete breakfast and lunch, perfect for keeping the calories down, through to our functional muesli and snack-tastic flapjacks.
Set up a monthly delivery of CholBiome® when it suits you for peace of mind. Help support healthy cholesterol levels month in, month out with automatic deliveries.
Take the weight off your mind and have SlimBiome® Medical delivered on a basis that suits you. Support your weight management goals and gut health without skipping a day.
Head over to OptiBiotix Online today and see how much you could save!
Order today at Optibiotix.online!
Do you know someone who could benefit from our subscribe and save service? Share it with them!
Share Share
Tweet Tweet
Forward Forward
Get more in return when you share the word! Refer a friend to the OptiBiotix Online Store and receive a £5 OptiBiotix Online Gift Voucher!
We love meeting and talking with new people, and helping individuals improve their health and well-being is what we strive for. Referring a new customer to the store who goes on to makes a purchase means you (the referrer) will receive a £5 OptiBiotix Online digital gift voucher to spend in-store. This is stackable, meaning each time you refer someone new, you get £5 to spend. The person you refer also gets a discount code providing 25% off their first order. It's a win-win situation!
For more information on this, head over to our website HERE.
i used to work for that shower how the hell they ever lasted so many years i will never know
12 February 2020
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Extension of LP(LDL) (R) into Dairy Products
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a licencing agreement with Granja Pocha S.A. ("Granja Pocha") for the inclusion of ProBiotix's patented probiotic strain LP(LDL) (R) into a functional yogurt product in Uruguay, South America.
Under the terms of the agreement, SACCO S.r.l., which helped develop the yogurt formulation, will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP(LDL) (R), under a non-exclusive licence to Granja Pocha for inclusion into fermented milk products, such as yogurts, in Uruguay, with the aim of maximising the financial return for both Granja Pocha and ProBiotix. There are no minimum sales targets in the licencing agreement.
Granja Pocha, was founded in 1980 in the main dairy basin of the Río de la Plata, Juan Lacaze, department of Colonia, Uruguay. Since 2013, they have sold products under the Colonial brand, including dulce de leche, cheeses, and yogurts. Granja Pocha describe themselves as having become one of Uruguay's largest and most respected dairy producers over the years.
Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with Granja Pocha, which will expand LP(LDL) (R)'s presence into South America and extends its use into dairy products. Granja Pocha was chosen as our partner to create a functional yogurt containing LP(LDL) (R) because of their technical expertise in dairy, track record of successfully launching new products, and extensive knowledge of the local market. The work carried out by Granja Pocha is a significant milestone as it extends the use of LP(LDL) (R) into functional foods, in this case dairy, which may be replicated in other territories. Functional foods like this yogurt containing ProBiotix's LP(LDL) (R) provide a unique format for customer to receive the cholesterol reducing benefits of LP(LDL) (R) and capitalises on a growing industry trend towards functional foods.
fantastic prog that was
willec those were his exact words how do you know that
yep he told me i would make loads buy into LGO he said, LOL
lancy very true i would trust LEO with life